Weill Cornell
Lexeo, Weill Cornell Data Rights Pact to Speed Development of FA Cardiomyopathy Gene Therapy
The firm has in-licensed data rights on LX2006 that will allow it to double the number of evaluable patients in clinical trials.
BriaCell Therapeutics, Weill Cornell Partner to Study Immunotherapy in Neoadjuvant TNBC
The investigator-initiated study will evaluate Bria-IMT plus a checkpoint inhibitor in early-stage, newly diagnosed, high-risk triple-negative breast cancer.
Astellas Bullish on Zolbetuximab's Prospects in Gastric Cancer After Two Positive Phase III Readouts
Premium
The firm will submit data from the GLOW and SPOTLIGHT studies to regulators and seek approval for zolbetuximab plus chemo in CLDN18.2-positive HER2-negative advanced gastric cancer.
Researchers at the Cleveland Clinic and beyond are applying biomarker strategies to a treatment modality that has historically missed out on precision oncology advances.
Immune Checkpoint Blockade Response Linked to Recurrent Mutations in Genes, Pathways
Exome sequences for hundreds of cancer patients led researchers to four recurrently mutated genes and several pathways with ties to immunotherapy response.